L14 #ACR22 Bimekizumab BE MOBILE 1 and 2 Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nrAxSpA, 45% AS) to W52 (61%, 58%). Efficacy in TNF-naive & TNF-failure. AEs: Nasopharyngitis (12% nrAxSpA, 9% AS), URI (9, 6%), candidiasis (7, 6%), COVID (7, 2%) @RheumNow https://t.co/G31PrfqtVu